This is attributed to the inhibition of ABC transporter activity namely ABCB1 and ABCG2 leading to increased retention of imatinib in CML cells (Glodkowska-Mrowka et al., 2014). Here, ABCG2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.